A program package for simulation and parameter estimation in pharmacokinetic systems.
about
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyEnhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activityAbsolute oral bioavailability of ciprofloxacinPhase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokineticsPharmacokinetic evaluation of two dosage regimens of clindamycin phosphateA simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men.Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.Pharmacokinetic parameters from data relating to the plasma and biliary excretion kinetics of cefmetazole in rats.Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins.Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applicationsBlast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.Pulmonary penetration of piperacillin and tazobactam in critically ill patients.Immunosuppressive interactions among calcium channel antagonists and selected corticosteroids and macrolides using human whole blood lymphocytes.Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancerPhase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplantsPopulation pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategyDevelopment and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.Effect of renal function on the bioavailability of ciprofloxacinPharmacokinetic analysis of cloxacillin loss in children undergoing major surgery with massive bleeding.Application of a Bayesian method to monitor and adjust vancomycin dosage regimensContinuous infusion of high-dose acyclovir for serious herpesvirus infections.Pharmacokinetics of teicoplanin in renal failureSteady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.Two administration methods for inhaled salbutamol in intubated patients.Relationships between renal function and disposition of oral ciprofloxacin
P2860
Q24519008-73DB8199-8152-43F7-A308-B960CA8BD863Q24682894-B740A50B-A6AD-4D96-B429-439BEBDCE4DFQ24685241-D3591A57-BB88-4F61-85EB-7C0DB2D504FDQ28346782-75660789-E64E-47CA-8C75-1B8F99644A72Q28353263-9CC9D068-355C-49EA-B8C9-6348FAEF041DQ28359157-ECAA1FC6-EEFD-4A43-8B49-1767F2BC3DABQ30657283-18C231CE-21A9-4F99-A771-4E6C239EFF89Q30864336-A83F31BF-5521-45D3-B745-321036D73E97Q30901836-8C969835-7474-48FA-A5F7-D374A87AB94DQ30919516-57D0D840-CE65-4882-878A-C26FF765DCC7Q33358701-384121B9-15D9-472C-92EF-FC9D8CB20130Q33559047-D1573000-ADED-463F-BAEB-371CC129BBAAQ33740530-C9DF83ED-C482-4934-B3EB-6D4F07F55B05Q33754929-B4E18D2F-CECC-4F6A-9227-6DF6AB627334Q34035750-C83960AB-5C4C-4470-A494-B4F322DCB5ECQ34109974-53851735-3532-4107-99D4-2823469FA0AEQ34134336-8E4680C3-44D1-4AE7-B77F-105F9BBDF665Q34134440-564D618A-2509-48A7-A634-5B7BC7D9AD61Q34157974-4BD0406C-C554-4DC2-93F2-C5FC946BA115Q34164704-6DFD34E2-B56D-4D08-9A6E-A382A0075932Q34216623-14B23E9A-5E3F-4323-9E08-8701194BB518Q34260591-F8F383C2-A96B-4452-A151-623B49A3E244Q34309574-13FB5E71-E52D-4594-AE7C-D06B53BF2724Q34398312-35A3415D-5AA6-4105-BF3C-4A8FF7A74C1EQ34549722-E50CA20D-300D-4CB4-8F8C-0955F3B58F80Q34554423-12242B89-1274-4A4D-8B31-8A8C718D33A0Q34824166-0B683362-349C-414C-8881-3F6057B6A470Q34926950-E2ED7317-5CC6-4A75-B244-4315D1D3BEDAQ35013781-5499F17D-92F0-47CB-84F6-E7E39280C6FDQ35118404-73E73779-9CE2-4C54-B5E5-E2E427FE3717Q35124143-208BB004-3AE8-478E-938E-CF42BDD0718CQ35126112-35F8B40E-03F9-40A0-A2FD-3227F14605FAQ35258939-EDE0AD18-4E8A-40E2-8B93-685C5530D41EQ35261431-16F7CF85-A720-48E8-931A-B1A43806E294Q35261758-6F609B0F-BE5C-4194-84BA-F6FE94209D68Q35345243-5947903C-C68A-4C9E-A06E-D29B06F71E03Q35541154-53274200-D333-457A-B006-8D1F760C40E7Q35541720-C2AB0CC9-28E4-4DCE-905E-05BD29A862F4Q35544935-D9EB0B6D-C0A9-464E-BD80-40F81E17342EQ35564482-197C72F9-79D0-4B1E-94D8-342D4CB51A31
P2860
A program package for simulation and parameter estimation in pharmacokinetic systems.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
A program package for simulation and parameter estimation in pharmacokinetic systems.
@en
type
label
A program package for simulation and parameter estimation in pharmacokinetic systems.
@en
prefLabel
A program package for simulation and parameter estimation in pharmacokinetic systems.
@en
P1476
A program package for simulation and parameter estimation in pharmacokinetic systems.
@en
P2093
D'Argenio DZ
Schumitzky A
P304
P356
10.1016/0010-468X(79)90025-4
P577
1979-03-01T00:00:00Z